Department of Rheumatology and Rehabilitation, Faculty of Medicine, Cairo University, Egypt.
Clin Exp Rheumatol. 2011 Mar-Apr;29(2):275-84. Epub 2011 Apr 19.
This study was intended to verify the likelihood of homing of intra-articularily injected mesenchymal stem cells (MSCs) and its involvement in the healing process of experimentally induced, acute and chronic, partial chondral defects in dogs.
Partial thickness chondral defects were created on the lateral femoral condyle of stifle joint in domestic mongrel dogs. MSCs were harvested in a separate procedure, labelled with green fluorescent protein (GFP) using monster GFP vector and suspended in buffer phosphate solution for intra-articular (IA) injection. Dogs were divided into three groups. Group I, served as the control. The dogs in the two cell-treated groups received a single IA injection of MSCs one day (Group II) and one month (Group III) after creating the defect. Sacrifice was scheduled at 2 and 8 weeks post-surgery for group I, and 2 and 8 weeks post-treatment, for the cell-treated groups. Morphological, histological, and fluorescence analysis was performed.
Recovery was significant both clinically and histologically in the two cell-treated groups (Group II and III) compared to the control (Group I), (p<0.001). In the meantime, Group-II showed better results at 8 weeks than Group III (p=0.01). Homing was confirmed by the incorporation of injected GFP-labelled MSCs within the newly formed cartilage.
The obtained results prove that the use of IA injection of autologous MSCs is a viable option for treating partial cartilage defects. Cell labelling gave evidence to the certainty of cell homing within the neocartilage of all treated cases and the participation in the reparative process.
本研究旨在验证关节内注射间充质干细胞(MSCs)的归巢可能性及其在犬实验性诱导的急性和慢性部分软骨缺损愈合过程中的作用。
在犬膝关节外侧股骨髁上造成部分厚度的软骨缺损。在单独的程序中收获 MSCs,使用怪物 GFP 载体标记绿色荧光蛋白(GFP),并悬浮在缓冲磷酸盐溶液中用于关节内(IA)注射。将狗分为三组。第 I 组作为对照组。在造成缺损后 1 天(第 II 组)和 1 个月(第 III 组),两组细胞处理组接受单次 IA MSCs 注射。第 I 组在手术后 2 周和 8 周,细胞处理组在治疗后 2 周和 8 周进行牺牲。进行形态学、组织学和荧光分析。
与对照组(第 I 组)相比,两组细胞处理组(第 II 组和第 III 组)在临床和组织学上均有显著恢复(p<0.001)。同时,第 II 组在 8 周时的结果优于第 III 组(p=0.01)。通过将注射的 GFP 标记 MSCs 整合到新形成的软骨中来证实归巢。
所得结果证明,IA 注射自体 MSCs 是治疗部分软骨缺损的可行选择。细胞标记证明了所有治疗病例的新软骨内细胞归巢的确定性以及参与修复过程。